Πλοήγηση ανά Συγγραφέα "Manns, M. P."
-
Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-alpha 2a treatment
Mederacke, I.; Yurdaydin, C.; Dalekos, G. N.; Bremer, B.; Erhardt, A.; Cakaloglu, Y.; Yalcin, K.; Gurel, S.; Zeuzem, S.; Zachou, K.; Bozkaya, H.; Dienes, H. P.; Manns, M. P.; Wedemeyer, H.; Hep-Net Int Delta Hepatitis, Study (2012)Background: The role of anti-HDV immunoglobulin M (IgM) testing in patients receiving pegylated interferon-alpha therapy for hepatitis delta is unknown. We performed anti-HDV IgM testing in a well defined cohort of HDVinfected ... -
ANTI-HDV-IGM TESTING IN HEPATITIS DELTA REVISITED: CORRELATIONS WITH DISEASE ACTIVITY AND RESPONSE TO PEGYLATED INTERFERON ALFA-2A TREATMENT
Mederacke, I.; Yurdaydin, C.; Bremer, B.; Cakaloglu, Y.; Erhardt, A.; Yalcin, K.; Zachou, K.; Gurel, S.; Heidrich, B.; Dalekos, G.; Dienes, H. P.; Manns, M. P.; Wedemeyer, H. (2010) -
Can response to pegylated interferon treatment in chronic delta hepatitis be predicted with on-treatment parameters?
Onder, F. O.; Erhardt, A.; Idilman, R.; Keskin, O.; Dalekos, G. N.; Yalcin, K.; Manns, M. P.; Wedemeyer, H.; Yurdaydin, C. (2012) -
Cross-genotype-reactivity of the immunodominant HCVCD8 T-cell epitope NS3-1073
Fytili, P.; Dalekos, G. N.; Schlaphoff, V.; Suneetha, P. V.; Sarrazin, C.; Zauner, W.; Zachou, K.; Berg, T.; Manns, M. P.; Klade, C. S.; Cornberg, M.; Wedemeyer, H. (2008)The HCV-specific HLA-A2-restricted NS3(1073) epitope is one of the most frequently recognized epitopes in hepatitis C. NS3(1073)-specific T-cell responses are associated with clearance of acute HCV-infection. Therefore ... -
Cytochrome P450 2A6: a new hepatic autoantigen in patients with chronic hepatitis C virus infection
Dalekos, G. N.; Obermayer-Straub, P.; Bartels, M.; Maeda, T.; Kayser, A.; Braun, S.; Loges, S.; Schmidt, E.; Gershwin, M. E.; Manns, M. P. (2003)Background/Aims: Cytochromes P4502A6 (CYP2A6) and P4501A2 (CYP1A2) were described as hepatic autoantigens in the autoimmune polyglandular syndrome type-1 (APS-1). We evaluated the significance of anti-CYP2A6 and anti-CYP1A2 ... -
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis
Liu, J. Z.; Hov, J. R.; Folseraas, T.; Ellinghaus, E.; Rushbrook, S. M.; Doncheva, N. T.; Andreassen, O. A.; Weersma, R. K.; Weismüller, T. J.; Eksteen, B.; Invernizzi, P.; Hirschfield, G. M.; Gotthardt, D. N.; Pares, A.; Ellinghaus, D.; Shah, T.; Juran, B. D.; Milkiewicz, P.; Rust, C.; Schramm, C.; Muler, T.; Srivastava, B.; Dalekos, G.; Nöthen, M. M.; Herms, S.; Winkelmann, J.; Mitrovic, M.; Braun, F.; Ponsioen, C. Y.; Croucher, P. J. P.; Sterneck, M.; Teufel, A.; Andrew, L. Mason; Saarela, J.; Leppa, V.; Dorfman, R.; Alvaro, D.; Floreani, A.; Onengut-Gumuscu, S.; Rich, S. S.; Thompson, W. K.; Schork, A. J.; Næss, S.; Thomsen, I.; Mayr, G.; König, I. R.; Hveem, K.; Cleynen, I.; Gutierrez-Achury, J.; Ricaño-Ponce, I.; Van Heel, D.; Björnsson, E.; Sandford, R. N.; Durie, P. R.; Melum, E.; Vatn, M. H.; Silverberg, M. S.; Duerr, R. H.; Padyukov, L.; Brand, S.; Sans, M.; Annese, V.; Achkar, J. P.; Boberg, K. M.; Marschall, H. U.; Chazouillères, O.; Bowlus, C. L.; Wijmenga, C.; Schrumpf, E.; Vermeire, S.; Albrecht, M.; Rioux, J. D.; Alexander, G.; Bergquist, A.; Cho, J.; Schreiber, S.; Manns, M. P.; Färkkilä, M.; Dale, A. M.; Chapman, R. W.; Konstantinos, N. Lazaridis; Franke, A.; Anderson, C. A.; Karlsen, T. H. (2013)Primary sclerosing cholangitis (PSC) is a severe liver disease of unknown etiology leading to fibrotic destruction of the bile ducts and ultimately to the need for liver transplantation. We compared 3,789 PSC cases of ... -
EFFICACY OF PEGYLATED INTERFERON-BASED TREATMENT IN PATIENTS WITH CIRRHOSIS DUE TO CHRONIC DELTA HEPATITIS: COMPARISON WITH NON-CIRRHOTIC PATIENTS
Yurdaydin, C.; Kobacam, G.; Cakaloglu, Y.; Erhardt, A.; Degertekin, H.; Gurel, S.; Zeuzem, S.; Dalekos, G. N.; Bozkaya, H.; Dienes, H. P.; Manns, M. P.; Wedemeyer, H. (2009) -
HBeAg-positive hepatitis delta: Virological patterns and clinical long-term outcome
Heidrich, B.; C. Serrano, B.; Idilman, R.; Kabaçam, G.; Bremer, B.; Raupach, R.; Önder, F. O.; Deterding, K.; Zacher, B. J.; Taranta, A.; Bozkaya, H.; Zachou, K.; Tillmann, H. L.; Bozdayi, A. M.; Manns, M. P.; Yurdaydin, C.; Wedemeyer, H. (2012)Background and Aims: The presence of the hepatitis B virus (HBV)-eAg in patients with hepatitis B is associated with higher HBV replication and with an increased risk to develop liver-related clinical endpoints defined as ... -
Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment
Grabowski, J.; Yurdaydìn, C.; Zachou, K.; Buggisch, P.; Hofmann, W. P.; Jaroszewicz, J.; Schlaphoff, V.; Manns, M. P.; Cornberg, M.; Wedemeyer, H. (2011)Background: Hepatitis delta is caused by infection with the hepatitis D virus (HDV) and is considered the most severe form of viral hepatitis. Treatment options for hepatitis delta are limited, with only 25% of patients ... -
Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece
Dalekos, G. N.; Makri, E.; Loges, S.; Obermayer-Straub, P.; Zachou, K.; Tsikrikas, T.; Schmidt, E.; Papadamou, G.; Manns, M. P. (2002)Objectives In Greece, there are insufficient data regarding the presence of non-organ and liver-related autoantibodies in hepatitis C patients. This study in a consecutive cohort of 39 such patients from central Greece ... -
Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta
Heidrich, B.; Yurdaydin, C.; Kabaçam, G.; Ratsch, B. A.; Zachou, K.; Bremer, B.; Dalekos, G. N.; Erhardt, A.; Tabak, F.; Yalcin, K.; Gürel, S.; Zeuzem, S.; Cornberg, M.; Bock, C. T.; Manns, M. P.; Wedemeyer, H. (2014)Interferon alpha is the only treatment option for hepatitis delta virus (HDV). Trials investigating the efficacy of pegylated interferon alpha (PEG-IFNa) showed HDV RNA negativity rates of 25-30% 24 weeks after therapy. ... -
LONG-TERM FOLLOW-UP AFTER PEG-IFNa2a-BASED THERAPY OF CHRONIC HEPATITIS DELTA
Heidrich, B.; Yurdaydin, C.; Kabacam, G.; Zachou, K.; Bremer, B.; Dalekos, G. N.; Erhardt, A.; Cakaloglu, Y.; Yalcin, K.; Gurel, S.; Zeuzem, S.; Bock, T.; Idilman, R.; Manns, M. P.; Wedemeyer, H. (2013) -
Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis
Zachou, K.; Yurdaydin, C.; Drebber, U.; Dalekos, G. N.; Erhardt, A.; Cakaloglu, Y.; Degertekin, H.; Gurel, S.; Zeuzem, S.; Bozkaya, H.; Schlaphoff, V.; Dienes, H. P.; Bock, T. C.; Manns, M. P.; Wedemeyer, H. (2010)Background: Hepatitis delta virus (HDV) causes severe liver disease. Aims: To investigate the quantitative HDV-RNA, HBsAg and hepatitis B virus (HBV)DNA levels in correlation to histological, biochemical and demographical ... -
Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection
Mederacke, I.; Yurdaydin, C.; Großhennig, A.; Erhardt, A.; Cakaloglu, Y.; Yalcin, K.; Gurel, S.; Zeuzem, S.; Zachou, K.; Chatzikyrkou, C.; Bozkaya, H.; Dalekos, G. N.; Manns, M. P.; Wedemeyer, H. (2012)Long-term safety of treatment with hepatitis B virus (HBV) polymerase inhibitors is a concern. Adefovir dipivoxil (ADV) therapy has previously been associated with impairment of renal function. Limited data are available ... -
Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience
Tillmann, H. L.; Hadem, J.; Leifeld, L.; Zachou, K.; Canbay, A.; Eisenbach, C.; Graziadei, I.; Encke, J.; Schmidt, H.; Vogel, W.; Schneider, A.; Spengler, U.; Gerken, G.; Dalekos, G. N.; Wedemeyer, H.; Manns, M. P. (2006)Acute hepatitis B progresses to liver failure with the need of liver transplantation in about 1% of cases. We treated patients with severe acute or fulminant hepatitis B with lamivudine in an attempt to prevent hepatitis ...